DSpace at RU >

Search Results

Results 1-50 of 174.

Item hits:

Full Text	Issue Date	Title	Author(s)
	2011	Bevacizumab and cancer treatment-related mortality	Punt, C.J.A.; Mol, L.; Koopman, M.
	2011	Cancer immunotherapy--revisited	Lesterhuis, W.J.; Haanen, J.B.; Punt, C.J.A.
	2011	MicroRNAs in colorectal cancer metastasis	Krijger, I. de; Mekenkamp, J.M.; Punt, C.J.A.; Nagtegaal, I.D.
	2011	The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery.	Bokkerink, G.M.; Graaf, E.J. de; Punt, C.J.; Nagtegaal, I.D.; Rütten, H.; Nuyttens, J.J.; Meerten, E. van; Doornebosch, P.G.; Tanis, P.J.; Derksen, E.J.; Dwarkasing, R.S.; Marijnen, C.A.; Cats, A.; Tollenaar, R.A.E.M.; Hingh, I.H.J.T. de; Rutten, H.J.; Schelling, G.P. van der; Tije, A. ten; Leijtens, J.W.; Lammering, G.; Beets, G.L.; Aufenacker, T.J.; Pronk, A.; Manusama, E.R.; Hoff, C.; Bremers, A.J.A.; Verhoef, C.G.; Wilt, J.H. de
	2011	Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer	Pander, J.; Wessels, J.A.M.; Gelderblom, H.; Straaten, T. van der; Punt, C.J.A.; Guchelaar, H.J.
	2011	Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer	Bruijn, M.T. de; Raats, D.A.; Tol, J.; Hinrichs, J.; Teerenstra, S.; Punt, C.J.A.; Rinkes, I.H.; Kranenburg, O.
	2011	The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients	Knijn, N.; Tol, J.; Koopman, M.; Werter, M.J.; Imholz, A.L.; Valster, F.A.; Mol, L.; Vincent, A.D.; Teerenstra, S.; Punt, C.J.A.
	2011	Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma	Wennekes, L.; Ottevanger, P.B.; Raemaekers, J.M.M.; Schouten, H.C.; Kok, M.W. de; Punt, C.J.A.; Grol, R.P.T.M.; Wollersheim, H.C.H.; Hermens, R.P.M.G.
	2011	Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer	Deenen, M.J.; Tol, J.; Burylo, A.M.; Doodeman, V.D.; Boer, A. de; Vincent, A.; Guchelaar, H.J.; Smits, P.H.; Beijnen, J.H.; Punt, C.J.A.; Schellens, J.H.; Cats, A.
	2011	Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy	Simkens, L.H.J.; Koopman, M.; Mol, L.; Veldhuis, G.J.; Bokkel Huinink, D. Ten; Muller, E.W.; Derleyn, V.A.; Teerenstra, S.; Punt, C.J.A.
	2011	Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature	Venderbosch, S.; Wilt, J.H. de; Teerenstra, S.; Loosveld, O.J.; Bochove, A. van; Sinnige, H.A.M.; Creemers, G.J.; Tesselaar, M.E.; Mol, L.; Punt, C.J.A.; Koopman, M.
	2011	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)	Patel, P.M.; Suciu, S.; Mortier, L.; Kruit, W.H.; Robert, C.; Schadendorf, D.; Trefzer, U.; Punt, C.J.A.; Dummer, R.; Davidson, N.; Becker, J.; Conry, R.; Thompson, J.A.; Hwu, W.J.; Engelen, K. van; Agarwala, S.S.; Keilholz, U.; Eggermont, A.M.M.; Spatz, A.
	2011	Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents	Vries, I.J.M. de; Castelli, C.; Huygens, C.; Jacobs, J.F.M.; Stockis, J.; Schuler-Thurner, B.; Adema, G.J.; Punt, C.J.A.; Rivoltini, L.; Schuler, G.; Coulie, P.G.; Lucas, S.
	2011	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice	Lesterhuis, W.J.; Punt, C.J.A.; Hato, S.V.; Eleveld-Trancikova, D.; Jansen, B.J.H.; Nierkens, S.; Schreibelt, G.; Boer, A. de; Herpen, C.M. van; Kaanders, J.H.A.M.; Krieken, J.H. van; Adema, G.J.; Figdor, C.G.; Vries, I.J.M. de
	2011	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients	Knijn, N.; Mekenkamp, L.; Klomp, M.; Vink-Borger, M.E.; Tol, J.; Teerenstra, S.; Meijer, J.W.; Tebar, M.; Riemersma, S.; Krieken, J.H. van; Punt, C.J.A.; Nagtegaal, I.D.
	2011	Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging	Aarntzen, E.H.J.G.; Srinivas, M.; Wilt, J.H. de; Jacobs, J.F.M.; Lesterhuis, W.J.; Windhorst, A.D.; Troost, E.G.C.; Bonenkamp, J.J.; Rossum, M.M. van; Blokx, W.A.M.; Mus, R.D.M.; Boerman, O.C.; Punt, C.J.A.; Figdor, C.G.; Oyen, W.J.G.; Vries, I.J.M. de
	2011	Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination	Mulder, S.F.; Jacobs, J.F.M.; Olde Nordkamp, M.A.M.; Galama, J.M.D.; Desar, I.M.E.; Torensma, R.; Teerenstra, S.; Mulders, P.F.; Vissers, K.C.P.; Punt, C.J.A.; Vries, I.J.M. de; Herpen, C.M.L. van
	2011	Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used	Lesterhuis, W.J.; Schreibelt, G.; Scharenborg, N.M.; Brouwer, H.M.; Gerritsen, M.J.P.; Croockewit, S.; Coulie, P.G.; Torensma, R.; Adema, G.J.; Figdor, C.G.; Vries, I.J.M. de; Punt, C.J.A.
	2011	Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients	Lesterhuis, W.J.; Vries, I.J.M. de; Schreibelt, G.; Lambeck, A.J.A.; Aarntzen, E.H.J.G.; Jacobs, J.F.M.; Scharenborg, N.M.; Rakt, M.W.M.M. van de; Boer, A.J. de; Croockewit, S.; Rossum, M.M. van; Mus, R.D.M.; Oyen, W.J.G.; Boerman, O.C.; Lucas, S.; Adema, G.J.; Punt, C.J.A.; Figdor, Carl
	2010	Drug development in advanced esophagogastric cancer: the art of extrapolation.	Punt, C.J.A.
	2010	Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'.	Pander, J.; Gelderblom, H.; Straaten, T. van der; Punt, C.J.A.; Guchelaar, H.J.
	2010	Assessment of Blood Hemodynamics by USPIO-Induced R(1) Changes in MRI of Murine Colon Carcinoma.	Laarhoven, H.W.M. van; Philippens, M.E.P.; Peeters, W.J.M.; Rijken, P.F.J.W.; Kogel, A.J. van der; Punt, C.J.A.; Heerschap, A.
	2010	The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab.	Simkens, L.H.J.; Tol, J.; Terstappen, L.W.; Teerenstra, S.; Punt, C.J.A.; Nagtegaal, I.D.
	2010	Current issues in the targeted therapy of advanced colorectal cancer.	Knijn, N.; Tol, J.; Punt, C.J.A.
	2010	A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.	Mol, L.; Koopman, M.; Ottevanger, P.B.; Punt, C.J.A.
	2010	Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases.	Mekenkamp, L.; Koopman, M.; Teerenstra, S.; Krieken, J.H.J.M. van; Mol, L.; Nagtegaal, I.D.; Punt, C.J.A.
	2010	Evidence-based medicine: the time has come to set standards for staging.	Quirke, P.; Cuvelier, C.; Ensari, A.; Glimelius, B.; Laurberg, S.; Ortiz, H.; Piard, F.; Punt, C.J.A.; Glenthoj, A.; Pennickx, F.; Seymour, M.; Valentini, V.; Williams, G.; Nagtegaal, I.D.
	2010	Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.	Bouwhuis, M.G.; Suciu, S.; Testori, A.; Kruit, W.H.; Sales, F.; Patel, P.; Punt, C.J.A.; Santinami, M.; Spatz, A.; Hagen, T.L.M. ten; Eggermont, A.M.M.
	2010	Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.	Cruijsen, H. van; Voest, E.E.; Punt, C.J.A.; Hoekman, K.; Witteveen, P.O.; Meijerink, M.R.; Puchalski, T.A.; Robertson, J.; Saunders, O.; Jurgensmeier, J.M.; Herpen, C.M.L. van; Giaccone, G.
	2010	High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue.	Tol, J.; Dijkstra, J.R.; Vink-Borger, M.E.; Nagtegaal, I.D.; Punt, C.J.A.; Krieken, J.H.J.M. van; Ligtenberg, M.J.L.
	2010	Immunogenicity of Dendritic Cells Pulsed with CEA Peptide or Transfected with CEA mRNA for Vaccination of Colorectal Cancer Patients.	Lesterhuis, W.J.; Vries, I.J.M. de; Schreibelt, G.; Schuurhuis, D.H.; Aarntzen, E.H.J.G.; Boer, A. de; Scharenborg, N.M.; Rakt, M.W.M.M. van de; Hesselink, E.J.; Figdor, C.G.; Adema, G.J.; Punt, C.J.A.
	2010	Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy.	Iersel, L.B. van; Koopman, M.; Velde, C.J. van de; Mol, L.; Persijn van Meerten, E.L. van; Hartgrink, H.H.; Kuppen, P.J.; Vahrmeijer, A.L.; Nortier, J.W.; Tollenaar, R.A.E.M.; Punt, C.J.A.; Gelderblom, H.
	2010	Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).	Laarhoven, H.W.M. van; Fiedler, W.; Desar, I.M.E.; Asten, J.J.A. van; Marreaud, S.; Lacombe, D.; Govaerts, A.S.; Bogaerts, J.; Lasch, P.; Timmer-Bonte, J.N.H.; Lambiase, A.; Bordignon, C.; Punt, C.J.A.; Heerschap, A.; Herpen, C.M.L. van
	2010	Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.	Schreibelt, G.; Benitez-Ribas, D.; Schuurhuis, D.; Lambeck, A.J.A.; Hout-Kuijer, M.A. van; Schaft, N.; Punt, C.J.A.; Figdor, C.G.; Adema, G.J.; Vries, I.J.M. de
	2010	A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.	Lesterhuis, W.J.; Vries, I.J.M. de; Aarntzen, E.H.J.G.; Boer, A. de; Scharenborg, N.M.; Rakt, M.W.M.M. van de; Spronsen, D.J. van; Preijers, F.W.M.B.; Figdor, C.G.; Adema, G.J.; Punt, C.J.A.
	2010	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.	Pander, J.; Gelderblom, H.; Antonini, N.F.; Tol, J.; Krieken, J.H.J.M. van; Straaten, T. van der; Punt, C.J.A.; Guchelaar, H.J.
	2010	Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.	Jacobs, J.F.M.; Punt, C.J.A.; Lesterhuis, W.J.; Sutmuller, R.P.M.; Brouwer, H.M.; Scharenborg, N.M.; Klasen, I.S.; Hilbrands, L.B.; Figdor, C.G.; Vries, I.J.M. de; Adema, G.J.
	2010	Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.	Tol, J.; Koopman, M.; Miller, M.C.; Tibbe, A.; Cats, A.; Creemers, G.J.; Vos, A.H.; Nagtegaal, I.D.; Terstappen, L.W.; Punt, C.J.A.
	2010	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.	Tol, J.; Punt, C.J.A.
	2010	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Peeters, M.; Price, T.J.; Cervantes, A.; Sobrero, A.F.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.J.A.; Strickland, A.H.; Wilson, G.; Ciuleanu, T.E.; Roman, L.; Cutsem, E. van; Tzekova, V.; Collins, S.; Oliner, K.S.; Rong, A.; Gansert, J.
	2010	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.	Tol, J.; Dijkstra, J.R.; Klomp, M.; Teerenstra, S.; Dommerholt, M.; Vink-Borger, M.E.; Cleef, P.H. van; Krieken, J.H.J.M. van; Punt, C.J.A.; Nagtegaal, I.D.
	2009	Chemotherapy, which drugs and when	Koopman, M.; Punt, C.J.A.
	2009	Current status of the systemic treatment of metastatic colorectal cancer : special report	Punt, C.J.A.; Mekenkamp, J.M.; Tol, J.; Koopman, M.
	2009	The CAIRO and FOCUS studies: which lesson is to be learned?	Koopman, M.; Seymour, M.T.; Punt, C.J.A.
	2009	BRAF mutation in metastatic colorectal cancer.	Tol, J.; Nagtegaal, I.D.; Punt, C.J.A.
	2009	Een combinatie van antilichamen bij gemetastaseerd colon- en rectum carcinoom leidt tot een slechtere progressievrije overleving: de CAIRO2-studie van de Dutch Colorectal Cancer Group	Tol, J.; Nagtegaal, I.D.; Punt, C.J.A.
	2009	Vascular endothelial growth factor in systemic capillary leak syndrome.	Lesterhuis, W.J.; Rennings, A.J.M.; Leenders, W.P.J.; Nooteboom, A.; Punt, C.J.A.; Sweep, C.G.J.; Pickkers, P.; Geurts-Moespot, A.; Laarhoven, H.W.M. van; Vlag, J. van der; Berden, J.H.M.; Postma, C.T.; Meer, J.W.M. van der
	2009	More is less -- combining targeted therapies in metastatic colorectal cancer.	Punt, C.J.A.; Tol, J.
	2009	Pylephlebitis after a duodenal ulcer in a patient with metastasised colon carcinoma treated with chemotherapy and bevacizumab: a case report.	Mannaerts, L.; Bleeker-Rovers, C.P.; Koopman, M.; Punt, C.J.A.; Herpen, C.M.L. van
	2009	Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.	Kweekel, D.M.; Antonini, N.F.; Nortier, J.W.; Punt, C.J.A.; Gelderblom, H.; Guchelaar, H.J.

1 2 3 4 next